DSM Biologics and Crucell Enter Licensing Deal
Tags: LICENSE agreements; KONINKLIJKE DSM NV; CRUCELL NV; LFB Biotechnologies SAS; PHARMACEUTICAL industry
Related Articles
- Collaborations: DSM Biologics and Crucell Announce Licensing Deal with LFB Biotechnologies. // Pharmaceutical Technology;Sep2007, Vol. 31 Issue 9, p134
The article reports that DSM Biologics of New Jersey and the biotechnology company Crucell NV of the Netherlands has signed a nonexclusive research licensing agreement with LFB Biotechnologies of Paris, France. It is stated that the LFB will use the PER.C6 production technology of Crucell to...
- DSM and Crucell license antibody technology to Sartorius. // PharmaWatch: Biotechnology;Jul2007, Vol. 6 Issue 7, p16
The article reports on the licensing agreement accorded by DSM Biologics and Crucell NV with Sartorius Biotech GmbH. The two companies have agreed to a non-exclusive PER.C6 research licensing deal with Sartorius. In addition, Sartorius will use Crucell's key technology to assess monoclonal...
- World Briefs. // Pharmaceutical Technology;Aug2008, Vol. 32 Issue 8, p22
The article offers world news briefs related to pharmaceutical industry. In Asia and Pacific, NovaMed Pharmaceuticals (Shanghai) and Pfizer China has formed a partnership in the oncology area in distributing oncology products throughout mainland China. In Europe, an agreement is made between DSM...
- News Watch. // European Chemical News;6/6/2005, Vol. 82 Issue 2150, p25
Presents news briefs concerning pharmaceutical industry as of June 2005. Research agreement signed by Codexis with Bristol-Myers Squibb to improve biocatalyst activity for a new Bristol-Myers Squibb candidate; Commercial license agreement signed by Crucell and DSM Biologics with Ferring...
- Crucell signs licensing deal. Tyler, Alan // European Chemical News;6/14/2004, Vol. 80 Issue 2104, p29
Reports on the research licensing deal signed by Dutch biotechnology player Crucell with PanGenetics. Significance of the deal to PanGenetics; Payment and annual maintenance fees to be received by Crucell and DSM Biologics; Description made by PanGenetics on itself.
- MorphoSys Signs Cooperative Agreements. // Pharmaceutical Technology;Oct2006, Vol. 30 Issue 10, p166
The article announces the license agreement signed by MorphoSys AG with Crucell NV and DSM Biologics. The agreement allows the former to use a cell line designed to produce clinical-grade material and develop its therapeutic human antibody program. The financial details of these agreements were...
- Pharmaceuticals & fine chemicals. // Chemical Week;1/1/2003, Vol. 165 Issue 1, p33
Presents news briefs on the chemical industry as of January 1, 2003. License deal signed by DSM Biologics with Crucell; Acquisition of the patents of Novozymes relating to the production of a recombinant enzyme for pharmaceutical applications by Solvay.
- Pharma CAPSULES. // Pharmaceutical Technology;Jan2007, Vol. 31 Issue 1, p106
The article offers news briefs related to the pharmaceutical industry. A new facility called PERCIVIA PER.C6 Development Center was opened by biotechnology company Crucell NV and technology partner DSM Biologics. A high-speed packaging line is planned by contract manufacturer Surefil LLC to...
- Innovations. // ICIS Chemical Business;1/15/2007, Vol. 2 Issue 49, p30
This section presents two international news briefs related to the chemical industry. A license agreement was signed by DSM Biologics and Dutch biotechnology partner Crucell with Portuguese biotechnology company Biotecnol and its U.S. subsidiary. Fluoropolymer producer Dyneon has bought...
